Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1624105 | 0.78 | KMT2A (0.54) | LMNARAB9AKMT2AMEN1NPC1 | |
| SCHEMBL27590552 | 0.68 | — | — | |
| SCHEMBL970055 | 0.67 | KMT2A (0.37) | LMNARAB9AKMT2AMEN1NPC1 | |
| SCHEMBL1639435 | 0.67 | — | — | |
| SCHEMBL4728163 | 0.65 | — | — | |
| SCHEMBL19900671 | 0.64 | KMT2A (0.78) | LMNARAB9AKMT2AMEN1NPC1 | |
| SCHEMBL28271180 | 0.64 | ENPP3 (0.31) | — | |
| SCHEMBL5550856 | 0.63 | ALDH1A1 (0.42) | LMNARAB9AKMT2AMEN1NPC1 | |
| SCHEMBL16678331 | 0.63 | KMT2A (0.37) | LMNARAB9AKMT2AMEN1NPC1 | |
| SCHEMBL1032107 | 0.63 | KMT2A (0.37) | LMNARAB9AKMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 436 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138831-B1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | HARVARD COLLEGE (US) | 2020-07-08 | — | — | EP | claimed |
| EP-3138831-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | President and Fellows of Harvard College (US) | 2017-03-08 | — | — | EP | claimed |
| EP-1546133-B1 | N-SUBSTITUTED-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS | BANYU PHARMA CO LTD (JP) | 2010-03-17 | — | — | EP | claimed |
| US-7531548-B2 | HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines | TIBOTEC PHARMACEUTICALS LTD (IE) | 2009-05-12 | — | — | US | claimed |
| US-20070208022-A1 | HIV INHIBITING 5-CARBO- OR HETEROCYCLYL SUBSTITUTED PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-09-06 | — | — | US | claimed |
| EP-0214029-B1 | 1-DETHIA-2-THIA CEPHALOSPORANIC-ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1992-03-25 | — | — | EP | claimed |
| WO-2024145435-A2 | LIPID COMPOSITIONS AND METHODS FOR DELIVERY TO IMMUNE CELLS | Life Technologies Corporation (US) | 2024-07-04 | — | — | WO | disclosed |
| US-11999754-B2 | Ruthenium complexes and their use in olefin metathesis reactions | APEIRON SYNTHESIS S.A. (PL) | 2024-06-04 | — | — | US | disclosed |
| WO-2024108116-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024108128-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-11976085-B2 | Process for producing ruthenium complexes and intermediates thereof and their use in olefin metathesis | Aperion Synthesis S.A. (PL) | 2024-05-07 | — | — | US | disclosed |
| WO-2024083802-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | VALDOSPAN GMBH (AT) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024073073-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-1997019053-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-05-29 | — | — | WO | disclosed |
| EP-0739336-A1 | GEM-DISUBSTITUTED AZACYCLIC TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1996-10-30 | — | — | EP | disclosed |
| WO-1995019344-A1 | GEM-DISUBSTITUTED AZACYCLIC TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1995-07-20 | — | — | WO | disclosed |
| US-5378721-A | AROMATASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0531759-A2 | Photographic silver halide photosensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 1993-03-17 | — | — | EP | disclosed |
| US-4376770-A | OXACEPHALOSPORINS | SHIONOGI & CO., LTD. (JP) | 1983-03-15 | — | — | US | disclosed |
| US-4198406-A | Carbamoyl heterocyclicthio cephalosporins and pharmaceutical compositions formulated therewith | BEECHAM GROUP LIMITED (GB) | 1980-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976085-B2 | Process for producing ruthenium complexes and intermediates thereof and their use in olefin metathesis | POR, CYP1B1, CYP4F11 | LMNA 4683/4885RAB9A 1773/4885KMT2A 4482/4885 |
| US-11999754-B2 | Ruthenium complexes and their use in olefin metathesis reactions | ADH1A, CYP2E1, OPRM1 | LMNA 4820/4885RAB9A 1743/4885KMT2A 4018/4885 |
| US-20070208022-A1 | HIV INHIBITING 5-CARBO- OR HETEROCYCLYL SUBSTITUTED PYRIMIDINES | CCNO, COX6C, CCR6 | LMNA 2006/4885RAB9A 2174/4885KMT2A 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.